Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 942.28
NAS:ABAX's Cash-to-Debt is ranked higher than
69% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. NAS:ABAX: 942.28 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ABAX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.21  Med: 227.05 Max: No Debt
Current: 942.28
0.21
No Debt
Equity-to-Asset 0.85
NAS:ABAX's Equity-to-Asset is ranked higher than
84% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. NAS:ABAX: 0.85 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ABAX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.86 Max: 0.92
Current: 0.85
0.51
0.92
Piotroski F-Score: 4
Altman Z-Score: 25.10
Beneish M-Score: -2.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 15.80
NAS:ABAX's Operating Margin % is ranked higher than
85% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. NAS:ABAX: 15.80 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ABAX' s Operating Margin % Range Over the Past 10 Years
Min: 12.42  Med: 16.77 Max: 21.18
Current: 15.8
12.42
21.18
Net Margin % 11.11
NAS:ABAX's Net Margin % is ranked higher than
80% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.48 vs. NAS:ABAX: 11.11 )
Ranked among companies with meaningful Net Margin % only.
NAS:ABAX' s Net Margin % Range Over the Past 10 Years
Min: 8.36  Med: 11.25 Max: 15.18
Current: 11.11
8.36
15.18
ROE % 9.80
NAS:ABAX's ROE % is ranked higher than
67% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.75 vs. NAS:ABAX: 9.80 )
Ranked among companies with meaningful ROE % only.
NAS:ABAX' s ROE % Range Over the Past 10 Years
Min: 7.67  Med: 10.07 Max: 16.35
Current: 9.8
7.67
16.35
ROA % 8.37
NAS:ABAX's ROA % is ranked higher than
81% of the 262 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.54 vs. NAS:ABAX: 8.37 )
Ranked among companies with meaningful ROA % only.
NAS:ABAX' s ROA % Range Over the Past 10 Years
Min: 6.77  Med: 8.81 Max: 14.32
Current: 8.37
6.77
14.32
ROC (Joel Greenblatt) % 45.14
NAS:ABAX's ROC (Joel Greenblatt) % is ranked higher than
82% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.57 vs. NAS:ABAX: 45.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ABAX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 31.2  Med: 43.41 Max: 64.69
Current: 45.14
31.2
64.69
3-Year Revenue Growth Rate 6.00
NAS:ABAX's 3-Year Revenue Growth Rate is ranked higher than
64% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. NAS:ABAX: 6.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ABAX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 4.5  Med: 13.8 Max: 166.8
Current: 6
4.5
166.8
3-Year EBITDA Growth Rate 2.40
NAS:ABAX's 3-Year EBITDA Growth Rate is ranked higher than
64% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. NAS:ABAX: 2.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ABAX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 18 Max: 215.3
Current: 2.4
0
215.3
3-Year EPS without NRI Growth Rate 8.70
NAS:ABAX's 3-Year EPS without NRI Growth Rate is ranked higher than
73% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. NAS:ABAX: 8.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ABAX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 15.9 Max: 159.6
Current: 8.7
0
159.6
GuruFocus has detected 6 Warning Signs with Abaxis Inc NAS:ABAX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ABAX's 30-Y Financials

Financials (Next Earnings Date: 2018-10-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

ABAX Guru Trades in Q3 2017

Chuck Royce 194 sh (New)
Jim Simons 122,271 sh (+91.35%)
PRIMECAP Management 2,218,300 sh (-2.72%)
Paul Tudor Jones 5,527 sh (-21.25%)
» More
Q4 2017

ABAX Guru Trades in Q4 2017

Steven Cohen 15,900 sh (New)
Joel Greenblatt 4,100 sh (New)
Jim Simons 162,971 sh (+33.29%)
Paul Tudor Jones 6,735 sh (+21.86%)
Chuck Royce 205 sh (+5.67%)
PRIMECAP Management 2,217,300 sh (-0.05%)
» More
Q1 2018

ABAX Guru Trades in Q1 2018

Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
PRIMECAP Management 2,216,300 sh (-0.05%)
Jim Simons 135,400 sh (-16.92%)
Steven Cohen 10,600 sh (-33.33%)
Chuck Royce 130 sh (-36.59%)
» More
Q2 2018

ABAX Guru Trades in Q2 2018

Mario Gabelli 123,800 sh (New)
Jim Simons 285,971 sh (+111.20%)
Chuck Royce 195 sh (+50.00%)
Steven Cohen Sold Out
PRIMECAP Management 2,089,108 sh (-5.74%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ABAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2018-06-30 New Buy0.07%$66.36 - $83.72 $ 83.008%123,800
Joel Greenblatt 2018-03-31 Sold Out $49.51 - $76 $ 83.0024%0
Joel Greenblatt 2017-12-31 New Buy$45.58 - $51.61 $ 83.0074%4,100
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 3826
Compare:SZSE:300685, SHSE:603108, NAS:KANG, SZSE:300439, NAS:VREX, NAS:MEDP, NAS:AXDX, NAS:BEAT, SHSE:600055, NAS:GHDX, SZSE:300396, SHSE:603127, TSE:4694, NSE:LALPATHLAB, NAS:ALOG, BSP:PARD3, NAS:MYGN, SZSE:300244, TSE:4282, NAS:QDEL » details
Traded in other countries:AXS.Germany,
Headquarter Location:USA
Abaxis Inc is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements.

Abaxis Inc manufactures point-of-care blood analysis instruments and consumables for medical and veterinary care providers. The medical segment sells Piccolo Chemistry Analyzers, which can provide results about a blood sample in 12 minutes, and related reagents to physicians, hospitals, pharmacies, and other healthcare providers. The veterinary segment generates the majority of the firm's total revenue and sells products to animal hospitals, veterinary clinics, and private research laboratories. Products in this segment include the VetScan VS2 chemistry analyzer, animal-specific reagents, and rapid tests for canine and feline diseases. The vast majority of the firm's revenue comes from North America and Europe.

Top Ranked Articles about Abaxis Inc

Mario Gabelli’s Top 5 New Buys of the 2nd Quarter Gabelli will speak at 2019 GuruFocus Value Conference
GAMCO Investments leader Mario Gabelli (Trades, Portfolio) disclosed 51 new positions when he released his second-quarter portfolio earlier this week. Read more...
Triumph Bancorp Set to Join S&P SmallCap 600
Lifshitz & Miller LLP Announces Investigation of Abaxis, Inc., AeroVironment, Inc., Gramercy Property Trust, Mitel Networks Corporation, Molina Healthcare, Inc., Rockwell Medical, Inc., and Symantec Corporation
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Abaxis, Inc. - ABAX
WeissLaw LLP Investigates Abaxis Inc.
Abaxis, Inc. to Present at the Bank of America Merrill Lynch 2018 Health Care Conference and the UBS Global Healthcare Conference
Research Report Identifies Jaguar Animal Health, Dollar Tree, WPX Energy, Abaxis, Lear, and Baker Hughes with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
Abaxis To Report Fourth Quarter And Fiscal Year 2018 Financial Results On Thursday, April 26, 2018
Abaxis, Inc. to Present at the Bank of America Merrill Lynch Animal Health Summit and the Raymond James 39th Annual Institutional Investors Conference
Abaxis, Inc. Announces USDA Approval of New VetScan FLEX4 Rapid Test

Ratios

vs
industry
vs
history
PE Ratio 70.94
ABAX's PE Ratio is ranked lower than
81% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.00 vs. ABAX: 70.94 )
Ranked among companies with meaningful PE Ratio only.
ABAX' s PE Ratio Range Over the Past 10 Years
Min: 20.75  Med: 41.66 Max: 75.53
Current: 70.94
20.75
75.53
Forward PE Ratio 52.08
ABAX's Forward PE Ratio is ranked lower than
90% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 52.08 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 70.94
ABAX's PE Ratio without NRI is ranked lower than
81% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.56 vs. ABAX: 70.94 )
Ranked among companies with meaningful PE Ratio without NRI only.
ABAX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 20.75  Med: 42.46 Max: 72.1
Current: 70.94
20.75
72.1
Price-to-Owner-Earnings 77.50
ABAX's Price-to-Owner-Earnings is ranked lower than
68% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.75 vs. ABAX: 77.50 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ABAX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 16.03  Med: 50.24 Max: 352.63
Current: 77.5
16.03
352.63
PB Ratio 6.48
ABAX's PB Ratio is ranked lower than
62% of the 245 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.02 vs. ABAX: 6.48 )
Ranked among companies with meaningful PB Ratio only.
ABAX' s PB Ratio Range Over the Past 10 Years
Min: 2.19  Med: 4.41 Max: 8.07
Current: 6.48
2.19
8.07
PS Ratio 7.85
ABAX's PS Ratio is ranked lower than
64% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.81 vs. ABAX: 7.85 )
Ranked among companies with meaningful PS Ratio only.
ABAX' s PS Ratio Range Over the Past 10 Years
Min: 2.48  Med: 4.93 Max: 8.56
Current: 7.85
2.48
8.56
Price-to-Free-Cash-Flow 51.11
ABAX's Price-to-Free-Cash-Flow is ranked lower than
66% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.22 vs. ABAX: 51.11 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ABAX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 21.44  Med: 43.93 Max: 101.82
Current: 51.11
21.44
101.82
Price-to-Operating-Cash-Flow 44.01
ABAX's Price-to-Operating-Cash-Flow is ranked lower than
71% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.94 vs. ABAX: 44.01 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ABAX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 17.16  Med: 32.36 Max: 78.82
Current: 44.01
17.16
78.82
EV-to-EBIT 44.80
ABAX's EV-to-EBIT is ranked lower than
71% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.06 vs. ABAX: 44.80 )
Ranked among companies with meaningful EV-to-EBIT only.
ABAX' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.6  Med: 26.6 Max: 46.3
Current: 44.8
10.6
46.3
EV-to-EBITDA 37.11
ABAX's EV-to-EBITDA is ranked lower than
73% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. ABAX: 37.11 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABAX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.7  Med: 21.65 Max: 38.4
Current: 37.11
8.7
38.4
EV-to-Revenue 7.08
ABAX's EV-to-Revenue is ranked lower than
60% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. ABAX: 7.08 )
Ranked among companies with meaningful EV-to-Revenue only.
ABAX' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.8  Med: 4.4 Max: 8.1
Current: 7.08
1.8
8.1
PEG Ratio 8.97
ABAX's PEG Ratio is ranked lower than
71% of the 48 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.26 vs. ABAX: 8.97 )
Ranked among companies with meaningful PEG Ratio only.
ABAX' s PEG Ratio Range Over the Past 10 Years
Min: 0.67  Med: 3.1 Max: 11.78
Current: 8.97
0.67
11.78
Shiller PE Ratio 82.45
ABAX's Shiller PE Ratio is ranked lower than
69% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.49 vs. ABAX: 82.45 )
Ranked among companies with meaningful Shiller PE Ratio only.
ABAX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 38.73  Med: 57.57 Max: 176.32
Current: 82.45
38.73
176.32
Current Ratio 6.02
ABAX's Current Ratio is ranked higher than
84% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. ABAX: 6.02 )
Ranked among companies with meaningful Current Ratio only.
ABAX' s Current Ratio Range Over the Past 10 Years
Min: 1.67  Med: 5.7 Max: 9.82
Current: 6.02
1.67
9.82
Quick Ratio 5.02
ABAX's Quick Ratio is ranked higher than
80% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. ABAX: 5.02 )
Ranked among companies with meaningful Quick Ratio only.
ABAX' s Quick Ratio Range Over the Past 10 Years
Min: 1.19  Med: 4.69 Max: 8.45
Current: 5.02
1.19
8.45
Days Inventory 134.87
ABAX's Days Inventory is ranked lower than
75% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.76 vs. ABAX: 134.87 )
Ranked among companies with meaningful Days Inventory only.
ABAX' s Days Inventory Range Over the Past 10 Years
Min: 100.6  Med: 123.54 Max: 136.57
Current: 134.87
100.6
136.57
Days Sales Outstanding 71.84
ABAX's Days Sales Outstanding is ranked higher than
57% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.51 vs. ABAX: 71.84 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABAX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 52.27  Med: 70.16 Max: 80.73
Current: 71.84
52.27
80.73
Days Payable 38.69
ABAX's Days Payable is ranked lower than
67% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. ABAX: 38.69 )
Ranked among companies with meaningful Days Payable only.
ABAX' s Days Payable Range Over the Past 10 Years
Min: 25.83  Med: 31.7 Max: 65.46
Current: 38.69
25.83
65.46

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.77
ABAX's Dividend Yield % is ranked higher than
54% of the 121 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.81 vs. ABAX: 0.77 )
Ranked among companies with meaningful Dividend Yield % only.
ABAX' s Dividend Yield % Range Over the Past 10 Years
Min: 0.21  Med: 0.88 Max: 1.27
Current: 0.77
0.21
1.27
Dividend Payout Ratio 0.51
ABAX's Dividend Payout Ratio is ranked lower than
57% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.32 vs. ABAX: 0.51 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ABAX' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.32  Med: 0.4 Max: 0.51
Current: 0.51
0.32
0.51
3-Year Dividend Growth Rate 14.50
ABAX's 3-Year Dividend Growth Rate is ranked lower than
99.99% of the 36 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.90 vs. ABAX: 14.50 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ABAX' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 14.5
Current: 14.5
0
14.5
Forward Dividend Yield % 0.87
ABAX's Forward Dividend Yield % is ranked lower than
52% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. ABAX: 0.87 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.77
ABAX's 5-Year Yield-on-Cost % is ranked lower than
68% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. ABAX: 0.77 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ABAX' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.21  Med: 0.88 Max: 1.27
Current: 0.77
0.21
1.27
3-Year Average Share Buyback Ratio -0.20
ABAX's 3-Year Average Share Buyback Ratio is ranked higher than
85% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.90 vs. ABAX: -0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABAX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23.8  Med: -3.05 Max: 0.4
Current: -0.2
-23.8
0.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 16.18
ABAX's Price-to-Net-Cash is ranked lower than
55% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.60 vs. ABAX: 16.18 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ABAX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 6.71  Med: 14 Max: 190.5
Current: 16.18
6.71
190.5
Price-to-Net-Current-Asset-Value 8.81
ABAX's Price-to-Net-Current-Asset-Value is ranked higher than
59% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.88 vs. ABAX: 8.81 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ABAX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.65  Med: 7.21 Max: 41.25
Current: 8.81
3.65
41.25
Price-to-Tangible-Book 6.50
ABAX's Price-to-Tangible-Book is ranked higher than
53% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.46 vs. ABAX: 6.50 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ABAX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.61  Med: 4.82 Max: 17.9
Current: 6.5
1.61
17.9
Price-to-Intrinsic-Value-Projected-FCF 3.39
ABAX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
61% of the 75 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. ABAX: 3.39 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ABAX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.85  Med: 2.89 Max: 16.39
Current: 3.39
1.85
16.39
Price-to-Intrinsic-Value-DCF (Earnings Based) 4.62
ABAX's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
88% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.86 vs. ABAX: 4.62 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
ABAX' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 1.2  Med: 3.9 Max: 4.5
Current: 4.62
1.2
4.5
Price-to-Median-PS-Value 1.59
ABAX's Price-to-Median-PS-Value is ranked lower than
68% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. ABAX: 1.59 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ABAX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.31  Med: 1.04 Max: 21.88
Current: 1.59
0.31
21.88
Price-to-Peter-Lynch-Fair-Value 9.51
ABAX's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.01 vs. ABAX: 9.51 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ABAX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.28  Med: 2.32 Max: 9.51
Current: 9.51
1.28
9.51
Price-to-Graham-Number 4.53
ABAX's Price-to-Graham-Number is ranked lower than
53% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.98 vs. ABAX: 4.53 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ABAX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.1  Med: 3.01 Max: 10
Current: 4.53
2.1
10
Earnings Yield (Greenblatt) % 2.23
ABAX's Earnings Yield (Greenblatt) % is ranked higher than
68% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. ABAX: 2.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ABAX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.2  Med: 3.8 Max: 9.5
Current: 2.23
2.2
9.5
Forward Rate of Return (Yacktman) % 8.92
ABAX's Forward Rate of Return (Yacktman) % is ranked lower than
56% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.45 vs. ABAX: 8.92 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ABAX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 5.7  Med: 15.8 Max: 23.1
Current: 8.92
5.7
23.1

More Statistics

Revenue (TTM) (Mil) $244.70
EPS (TTM) $ 1.17
Volatility51.22%
52-Week Range $43.66 - 83.98
Shares Outstanding (Mil)22.87

Analyst Estimate

Mar19 Mar20 Mar21
Revenue (Mil $) 282 305 325
EBIT (Mil $) 49 54 61
EBITDA (Mil $) 56 62 69
EPS ($) 1.61 1.82 2.01
EPS without NRI ($) 1.61 1.82 2.01
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($) 3.35 3.68 4.05

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}